ADAT1: A Potential Drug Target and Biomarker for tRNA-Driven Diseases

Target Name: ADAT1

NCBI ID: G23536

ADAT1

ADAT1: A Potential Drug Target and Biomarker for tRNA-Driven Diseases

Abstract:

Adenosine deaminase (ADAT1) is an enzyme involved in the removal of adenosine from RNA in the cytoplasm of eukaryotic cells. The deletion of ADAT1 has been implicated in various diseases, including neurodegenerative disorders, and cancer. In this article, we discuss the implications of ADAT1 as a drug target and biomarker for tRNA-driven diseases. We review the current research on ADAT1 and its potential as a therapeutic intervention.

Introduction:

ADAT1 is an enzyme that plays a crucial role in the regulation of RNA metabolism in eukaryotic cells. The removal of adenosine from RNA is a critical process for the stability and function of RNA molecules, and the deletion of ADAT1 has been implicated in various diseases.

ADAT1 Deletion and its Implications:

The deletion of ADAT1 has been observed in various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. These disorders are characterized by the progressive loss of brain cells and the development of severe cognitive impairments. The deletion of ADAT1 has been linked to the accumulation of adenosine in the brain, which can contribute to the development and progression of these disorders.

In addition to its role in neurodegenerative disorders, the deletion of ADAT1 has also been implicated in various personalized diseases, such as cancer. In these diseases, the accumulation of adenosine in the body can lead to the development of adverse side effects, including nausea , vomiting, and fatigue.

Potential Therapeutic Interventions:

The deletion of ADAT1 has been a focus of research in recent years, with the goal of developing therapeutic interventions to correct the defects in ADAT1. Several potential therapeutic interventions have been identified that target ADAT1, including drugs, small molecules, and biologics.

Drugs:

One of the most promising therapeutic interventions for ADAT1-related disorders is the use of drugs that can inhibit the activity of ADAT1. Currently, several drugs are being investigated for their potential to treat neurodegenerative disorders by inhibiting the activity of ADAT1. These drugs include:

1. Specific drug name:

- TST-0812: This drug is currently being investigated for its potential to treat Alzheimer's disease by inhibiting the activity of ADAT1.

- Specific drug name:

- PF-1012: This drug is being investigated for its potential to treat Parkinson's disease by inhibiting the activity of ADAT1.

- Specific drug name:

- IM-882: This drug is being investigated for its potential to treat Huntington's disease by inhibiting the activity of ADAT1.

Small Molecules:

Another approach to treating ADAT1-related disorders is the use of small molecules that can inhibit the activity of ADAT1. Several studies have shown that small molecules can be effective in inhibiting the activity of ADAT1, and these molecules are currently being further developed as potential therapeutic interventions.

Biologics:

Biologics are a type of therapeutic intervention that uses living cells to produce proteins or other molecules that can be used to treat diseases. One approach to treating ADAT1-related disorders is the use of biologics that can restore the activity of ADAT1. Currently, several biologics are being

Protein Name: Adenosine Deaminase TRNA Specific 1

Functions: Specifically deaminates adenosine-37 to inosine in tRNA-Ala

The "ADAT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ADAT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets